Korro Bio, Inc. Operating Lease Cost
Korro Bio, Inc. (KRRO) reported Operating Lease Cost of $1.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-06
- Korro Bio, Inc. operating lease, cost for the quarter ending 2026-06-30 was $1.39M, a 1.42% decline year-over-year.
- Korro Bio, Inc. operating lease, cost for the quarter ending 2026-03-31 was $1.42M, a 0.85% increase year-over-year.
- Korro Bio, Inc. operating lease, cost for the quarter ending 2025-12-31 was $1.40M, a 2.51% decline year-over-year.
- Korro Bio, Inc. operating lease, cost for the quarter ending 2025-09-30 was $1.41M, a 27.23% decline year-over-year.
- Korro Bio, Inc. operating lease, cost for fiscal 2025 was $5.63M, a 26.20% decline from fiscal 2024.
- Korro Bio, Inc. operating lease, cost for fiscal 2024 was $7.63M, a 28.26% increase from fiscal 2023.
- Korro Bio, Inc. operating lease, cost for fiscal 2023 was $5.95M, a 255.10% increase from fiscal 2022.
- Korro Bio, Inc. operating lease, cost for fiscal 2022 was $1.68M.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.39M 10-Q · filed 2026-08-06 | $2.81M 10-Q · filed 2026-08-06 | $4.21M derived: sum of 3 quarters · filed 2026-08-06 | $5.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.42M 10-Q · filed 2026-05-07 | $2.82M derived: sum of 2 quarters · filed 2026-05-07 | $4.23M derived: sum of 3 quarters · filed 2026-05-07 | $5.64M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.81M derived: sum of 2 quarters · filed 2026-03-12 | $4.22M derived: sum of 3 quarters · filed 2026-08-06 | $5.63M 10-K · filed 2026-03-12 |
| 2025-09-30 | $1.41M 10-Q · filed 2025-11-12 | $2.82M derived: sum of 2 quarters · filed 2026-08-06 | $4.23M 10-Q · filed 2025-11-12 | $5.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.41M 10-Q · filed 2026-08-06 | $2.82M 10-Q · filed 2026-08-06 | $4.25M derived: sum of 3 quarters · filed 2026-08-06 | $6.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.41M 10-Q · filed 2026-05-07 | $2.84M derived: sum of 2 quarters · filed 2026-05-07 | $4.78M derived: sum of 3 quarters · filed 2026-05-07 | $6.89M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.37M derived: sum of 2 quarters · filed 2026-03-12 | $5.48M derived: sum of 3 quarters · filed 2026-03-12 | $7.63M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.94M 10-Q · filed 2025-11-12 | $4.05M derived: sum of 2 quarters · filed 2025-11-12 | $6.20M 10-Q · filed 2025-11-12 | $8.35M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $2.11M 10-Q · filed 2025-08-12 | $4.26M 10-Q · filed 2025-08-12 | $6.41M derived: sum of 3 quarters · filed 2025-08-12 | $8.30M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.15M 10-Q · filed 2025-05-07 | $4.30M derived: sum of 2 quarters · filed 2025-05-07 | $6.20M derived: sum of 3 quarters · filed 2025-05-07 | $7.62M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $4.05M derived: sum of 2 quarters · filed 2025-03-18 | $5.47M derived: sum of 3 quarters · filed 2025-03-18 | $5.95M 10-K · filed 2025-03-18 |
| 2023-09-30 | $1.89M 10-Q · filed 2024-11-12 | $3.31M derived: sum of 2 quarters · filed 2024-11-12 | $3.79M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $1.42M 10-Q · filed 2024-08-13 | $1.90M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $481.00K 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $1.68M 10-K · filed 2024-03-26 | |||
| 2020-12-31 | $113.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $238.00K derived: sum of 2 quarters · filed 2021-03-29 | $363.00K derived: sum of 3 quarters · filed 2021-03-29 | $470.00K 10-K · filed 2021-03-29 |
| 2020-09-30 | $125.00K 10-Q · filed 2020-11-16 | $250.00K derived: sum of 2 quarters · filed 2020-11-16 | $357.00K 10-Q · filed 2020-11-16 | |
| 2020-06-30 | $125.00K 10-Q · filed 2020-08-12 | $232.00K 10-Q · filed 2020-08-12 | ||
| 2020-03-31 | $107.00K 10-Q · filed 2020-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |